Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Kimberly

Rheumatology Birmingham, AL Medical Doctor

NPI 1750318267 CMS profile 839977

1717 6Th Ave S, Birmingham, AL 35233

Open in the dashboard

General payments

$803

8 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Kimberly of Birmingham, AL is reported in the CMS Open Payments database as having received $803 across 8 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $443 4
2022 General $142 2
2019 General $218 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Kimberly
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Robert Kimberly were reported at $443. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Robert Kimberly Rheumatology median Middle half National median
2019 $218 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $142 $627 $125–$2,303 $149
2023 $0 $741 $145–$2,524 $160
2024 $0 $830 $166–$2,660 $164
2025 $443 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $205 2 payments
  2. Argenx US, Inc. $137 1 payment
  3. Alexion Pharmaceuticals, Inc. $125 1 payment
  4. UCB, Inc. $125 1 payment
  5. Regeneron Healthcare Solutions, Inc. $122 1 payment
  6. Novartis Pharmaceuticals Corporation $73 1 payment
  7. Takeda Pharmaceuticals U.S.A., Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $803 8 payments
Products named General payments · program years 2019–2025
  1. VYVGART Hytrulo $137 1 payment
  2. Bimzelx $125 1 payment
  3. KEVZARA $122 1 payment
  4. NUCALA $96 1 payment
  5. CUVITRU $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

182

Median for Rheumatology: 1,511

Drug cost

$6,827

Median for Rheumatology: $1,139,948

Branded share of claims

37.9%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydroxychloroquine Sulfate Generic 27 $2,508
Celecoxib Generic 19 $1,180
Diclofenac Sodium Generic 13 $913
Methotrexate Methotrexate Sodium Brand 40 $755
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $652
Alprazolam Generic 13 $375
Prednisone Generic 18 $263
Clonazepam Generic 11 $108
Meloxicam Generic 12 $74

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Records

8 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record